ANDREA STENGEL: Open Payments
NPI 1235225871 · HAUPPAUGE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 20 payments from 8 companies in 2025. Trend: 2023 $165 · 2024 $323 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $324 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $151 |
| Teva Pharmaceuticals USA, Inc. | 4 | $125 |
| E.R. Squibb & Sons, L.L.C. | 2 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $17 |
| Merck Sharp & Dohme LLC | 1 | $15 |
Products named: INGREZZA, CAPLYTA, AUSTEDO XR, COBENFY, HETLIOZ, UZEDY, REXULTI, ARISTADA.
Industry payments across NY — which companies pay providers there.
